Evidence map›Paper›PMID 37326917›Full record

ReviewClinical pharmacokinetics2023

Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule.

Zaid H Temrikar, Jennifer E Golden, Colleen B Jonsson, Bernd Meibohm

Abstract readReview
In one paragraph

Review in Clinical pharmacokinetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Frontiers in veterinary science · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zaid H TemrikarDepartment of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN, 38163, USA.
Jennifer E GoldenPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, WI, USA.
Colleen B JonssonDepartment of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN, 38163, USA.
Bernd MeibohmDepartment of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN, 38163, USA. bmeibohm@uthsc.edu.ORCID http://orcid.org/0000-0003-3923-3648

Funding

Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5M
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target EngagementU19AI142762 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JONSSON, COLLEEN B · 2019 to 2023
$22.0M
NIAID NIH HHS U19 AI142762NIAID NIH HHS U19 AI171292
6 · The paper itself

Abstract

The US Food and Drug Administration's Animal Rule provides a pathway for approval of drugs and biologics aimed to treat serious or life-threatening conditions wherein traditional clinical trials are either not ethical or feasible. In such a scenario, determination of safety and efficacy are based on integration of data on drug disposition and drug action collected from in vitro models, infected animals, and healthy volunteer human studies. The demonstration of clinical efficacy and safety in humans based on robust, well-controlled animal studies is filled with challenges. This review elaborates on the challenges in the translation of data from in vitro and animal models to human dosing for antimicrobials. In this context, it discusses precedents of drugs approved under the Animal Rule, along with the approaches and guidance undertaken by sponsors.

Indexed as

Anti-Infective AgentsDrug ApprovalAnimalsBiological FactorsHumansPharmaceutical PreparationsUnited StatesUnited States Food and Drug AdministrationAnti-Infective AgentsBiological FactorsPharmaceutical Preparations

Identifiers

PMID37326917
PMCPMC10471120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.